Company intelligence

TVRD

Price—Latest market price

Market cap—Equity value

P / E—Trailing ratio

Volume—Latest session

Market data

TVRD price chart

TradingView

Related signals

1 min delayed

Browse public TVRD signals with their source context and measured market impact. Open any signal for its permanent analysis page.

TVRDOct 13, 2025+5.11% since signal

Tvardi Therapeutics' Lung Disease Candidate Fails To Show Any Clinical Benefit, Stock Sinks

Tvardi's stock fell 84.18% to $6.58 after trial update. Phase 2 REVERT trial did not meet efficacy goals. Discontinuation rates higher for TTI-101 in IPF patients. FVC improvement similar between placebo and treatment arms. Company has $41 million to fund operations through 2026.

View signal analysis

TVRDJun 12, 2025-7.09% since signal

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

Tvardi completed its merger with Cara Therapeutics in April. The company’s lead drug, TTI-101, is in Phase 2 for IPF. Piper Sandler initiated coverage, rating TVRD as overweight with $78 target. TVRD is well-funded, expected to last into the second half of 2026. TTI-109, a next-gen drug, is also under development for STAT3.

View signal analysis

Research